B16F10 melanoma cell line in vitro has low MHC-I expression due to a reversible TAP2 deficiency [41], while in vivo the MHC-I status of this tumor type is regulated by the microenvironment, mainly by IFNγ produced by the tumor-infiltrating NK and γδT cells which are recruited rapidly to B16F10 subcutaneous grafts [42]. The gene discussed is TAP2; the disease is neoplasm.